Medical Professionals Reference (MPR)Oral GLP-1 Foundayo Approved for Weight Reduction in Obesity, Overweight

The FDA approved Foundayo (orforglipron), the first oral once-daily GLP-1 receptor agonist, for weight reduction in adults with obesity or overweight with at least one comorbidity. Across two phase 3 trials in 4,740 patients, the highest dose produced 11.1% body weight reduction in nondiabetic adults versus 2.1% for placebo at 72 weeks.

Professional Impact

• Patients on oral hormonal contraceptives must switch to non-oral or add barrier methods for 30 days after initiation and after each dose escalation due to delayed gastric emptying
• Foundayo must be discontinued upon confirmed pregnancy and carries a boxed warning for thyroid C-cell tumors
• The oral tablet format removes injection barriers that prevented many patients from starting injectable GLP-1 therapy
• Cardiometabolic benefits included improvements in HbA1c, LDL, triglycerides, and blood pressure alongside weight reduction

Action Items

• Review all patients on oral contraceptives before prescribing Foundayo and counsel on contraceptive switching
• Screen for personal or family history of medullary thyroid carcinoma or MEN2 before prescribing
• Counsel patients that dose titration starts at 0.8mg with minimum 30-day intervals between escalations
• Document pregnancy intent discussions, as delayed gastric emptying affects oral medication absorption broadly

More in GLP-1s